​

CG Oncology (CGON) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChart

CGON Stock Forecast

CG Oncology (CGON) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $62.33, with a high of $75.00 and a low of $52.00. This represents a 105.78% increase from the last price of $30.29.

$25 $35 $45 $55 $65 $75 High: $75 Avg: $62.33 Low: $52 Last Closed Price: $30.29

CGON Stock Rating

CG Oncology stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

CGON Forecast vs Benchmarks

TypeNameUpside
StockCG Oncology105.78%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$59.25
Last Closing Price$30.29$30.29$30.29
Upside/Downside--95.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2535---8
Dec, 2444---8
Nov, 2446---10
Oct, 2456---11
Sep, 2456---11
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 24, 2024David DaiUBS$60.00$35.6168.49%98.09%
Sep 17, 2024Andres MaldonadoH.C. Wainwright$75.00$37.9497.68%147.61%
Sep 16, 2024Corinne JohnsonGoldman Sachs$52.00$34.8049.43%71.67%
May 13, 2024Corinne JohnsonGoldman Sachs$50.00$25.8493.50%65.07%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Jan 10, 2025H.C. WainwrightBuyBuyhold
Oct 24, 2024UBSBuyinitialise
Oct 21, 2024Goldman SachsBuyBuyhold
Sep 23, 2024RBC CapitalOutperforminitialise
Sep 17, 2024H.C. WainwrightBuyBuyhold
Sep 16, 2024Johnson RiceBuyBuyhold
Sep 16, 2024Goldman SachsBuyBuyhold
Jun 28, 2024H.C. WainwrightUnderperformUnderperformhold
Jun 28, 2024Bank of America SecuritiesBuyinitialise
May 14, 2024Morgan StanleyBuyBuyhold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.73-----
Avg Forecast$-1.33$-1.28$-1.76$-1.40$-1.20$0.67
High Forecast$-1.43$-1.37$-1.99$-2.77$-2.39$0.01
Low Forecast$-1.15$-1.21$-1.51$-0.02$-0.02$1.34
Surprise %-45.11%-----

Revenue Forecast

$0 $140M $280M $420M $560M $700M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$204.00K-----
Avg Forecast$100.75K$1.28M$3.49M$99.15M$175.75M$395.91M
High Forecast$24.30K$409.27K$842.88K$23.92M$42.39M$95.50M
Low Forecast$177.20K$2.15M$6.15M$174.38M$309.11M$696.33M
Surprise %102.48%-----

Net Income Forecast

$-50M $-38M $-26M $-14M $-2M $10M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-48.61M-----
Avg Forecast$-5.77M$-5.54M$-7.60M$-6.04M$-5.21M$2.91M
High Forecast$-6.17M$-5.92M$-8.64M$-12.00M$-10.35M$39.52K
Low Forecast$-4.97M$-5.24M$-6.53M$-81.98K$-70.66K$5.79M
Surprise %742.27%-----

CGON Forecast FAQ

Is CG Oncology stock a buy?

CG Oncology stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that CG Oncology is a favorable investment for most analysts.

What is CG Oncology's price target?

CG Oncology's price target, set by 7 Wall Street analysts, averages $62.33 over the next 12 months. The price target range spans from $52 at the low end to $75 at the high end, suggesting a potential 105.78% change from the previous close price of $30.29.

How does CG Oncology stock forecast compare to the average forecast of its sector, industry, and investment themes?

CG Oncology stock forecast shows a 105.78% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for CG Oncology over the past three months?

  • January 2025: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is CG Oncology’s EPS forecast?

CG Oncology's average annual EPS forecast for its fiscal year ending in December is -1.28 for 2024, a 75.34% increase from the reported $-0.73 in 2023. The prediction for 2025 is $-1.76, $-1.4 for 2026, $-1.2 for 2027, and $0.67 for 2028.

What is CG Oncology’s revenue forecast?

CG Oncology's average annual revenue forecast for its fiscal year ending in December is $1.28M for 2024, a 527.67% increase from the reported $204K in 2023. The forecast for 2025 is $3.49M, $99.15M for 2026, $175.75M for 2027, and $395.91M for 2028.

What is CG Oncology’s net income forecast?

For its fiscal year ending in December, CG Oncology's average annual net income forecast is $-5.541M for 2024, reflecting a -88.60% decrease from the reported $-48.607M in 2023. The projection for 2025 is $-7.605M, $-6.042M for 2026, $-5.208M for 2027, and $2.91M for 2028.